See more : hyungji Elite Co., Ltd. (093240.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Abbott Laboratories (ABT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abbott Laboratories, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Hire Technologies Inc. (HIRRF) Income Statement Analysis – Financial Results
- Shanxi Changcheng Microlight Equipment Co. Ltd. (8286.HK) Income Statement Analysis – Financial Results
- Asia Standard Hotel Group Limited (0292.HK) Income Statement Analysis – Financial Results
- Apollo Global Management, Inc. (APO-PA) Income Statement Analysis – Financial Results
- Union Metallurgique de la Haute-Seine S.A. (MLUMH.PA) Income Statement Analysis – Financial Results
Abbott Laboratories (ABT)
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.11B | 43.65B | 43.08B | 34.61B | 31.90B | 30.58B | 27.39B | 20.85B | 20.41B | 20.25B | 21.85B | 39.87B | 38.85B | 35.17B | 30.77B | 29.53B | 25.91B | 22.48B | 22.34B | 19.68B | 19.68B | 17.68B | 16.29B | 13.75B | 13.18B | 12.48B | 11.88B | 11.01B | 10.01B | 9.16B | 8.41B | 7.85B | 6.88B | 6.16B | 5.38B | 4.94B | 4.39B | 3.81B | 3.36B |
| Cost of Revenue | 17.98B | 19.14B | 18.54B | 15.00B | 13.23B | 12.71B | 12.34B | 9.02B | 8.75B | 9.22B | 10.04B | 15.12B | 15.54B | 14.67B | 13.21B | 12.61B | 11.42B | 9.82B | 10.64B | 8.88B | 9.47B | 8.51B | 7.75B | 6.24B | 5.98B | 5.39B | 5.05B | 4.73B | 4.33B | 3.99B | 3.68B | 3.08B | 2.76B | 2.55B | 2.25B | 2.08B | 1.86B | 1.67B | 1.54B |
| Gross Profit | 22.13B | 24.51B | 24.54B | 19.61B | 18.67B | 17.87B | 15.05B | 11.83B | 11.66B | 11.03B | 11.81B | 24.75B | 23.31B | 20.50B | 17.56B | 16.92B | 14.49B | 12.66B | 11.70B | 10.80B | 10.21B | 9.18B | 8.54B | 7.51B | 7.20B | 7.08B | 6.84B | 6.28B | 5.69B | 5.16B | 4.72B | 4.77B | 4.12B | 3.60B | 3.13B | 2.85B | 2.53B | 2.14B | 1.82B |
| Gross Profit Ratio | 55.18% | 56.15% | 56.97% | 56.65% | 58.53% | 58.45% | 54.96% | 56.73% | 57.13% | 54.47% | 54.05% | 62.08% | 60.00% | 58.30% | 57.06% | 57.29% | 55.92% | 56.33% | 52.36% | 54.86% | 51.86% | 51.90% | 52.42% | 54.61% | 54.64% | 56.77% | 57.54% | 57.03% | 56.79% | 56.38% | 56.18% | 60.81% | 59.85% | 58.53% | 58.19% | 57.82% | 57.65% | 56.17% | 54.19% |
| Research & Development | 2.74B | 2.89B | 2.74B | 2.42B | 2.44B | 2.30B | 2.24B | 1.42B | 1.41B | 1.35B | 1.45B | 4.32B | 4.80B | 3.73B | 2.74B | 2.69B | 2.51B | 2.26B | 1.82B | 1.70B | 1.73B | 1.56B | 1.58B | 1.35B | 1.19B | 1.22B | 1.30B | 1.20B | 1.07B | 963.52M | 880.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.74B | 9.12B | 6.67B | 6.79B | 6.53B | 6.94B | 12.06B | 12.76B | 10.38B | 8.41B | 8.44B | 7.41B | 6.35B | 5.50B | 4.92B | 5.05B | 3.98B | 3.73B | 2.89B | 2.86B | 2.74B | 2.68B | 2.46B | 2.23B | 2.05B | 1.99B | 2.82B | 2.18B | 1.84B | 1.60B | 1.48B | 1.28B | 1.06B | 928.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -495.00K | -817.00K | -324.00K | 96.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.95B | 11.25B | 11.32B | 9.70B | 9.77B | 9.74B | 9.12B | 6.67B | 6.79B | 6.53B | 6.94B | 12.06B | 12.76B | 10.38B | 8.41B | 8.44B | 7.41B | 6.35B | 5.50B | 4.92B | 5.05B | 3.98B | 3.73B | 2.89B | 2.86B | 2.74B | 2.68B | 2.46B | 2.23B | 2.05B | 1.99B | 2.82B | 2.18B | 1.84B | 1.60B | 1.48B | 1.28B | 1.06B | 928.20M |
| Other Expenses | 1.97B | 2.01B | 2.05B | 2.13B | 1.94B | 139.00M | 1.25B | -945.00M | 281.00M | -14.00M | 32.00M | 34.00M | -119.00M | 62.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -138.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -70.00M | 427.80M | 379.00M | 355.90M | 307.30M | 270.90M | 243.70M | 199.50M | 155.80M |
| Operating Expenses | 15.66B | 16.15B | 16.11B | 14.25B | 14.14B | 14.22B | 13.33B | 8.64B | 8.79B | 8.43B | 9.18B | 16.38B | 17.56B | 14.10B | 11.15B | 11.12B | 9.91B | 8.60B | 7.32B | 6.62B | 6.78B | 5.54B | 5.31B | 4.11B | 4.05B | 3.97B | 3.99B | 3.66B | 3.30B | 3.02B | 2.80B | 3.25B | 2.56B | 2.20B | 1.91B | 1.75B | 1.52B | 1.26B | 1.08B |
| Cost & Expenses | 33.63B | 35.29B | 34.65B | 29.25B | 27.37B | 26.93B | 25.66B | 17.67B | 17.54B | 17.65B | 19.22B | 31.50B | 33.10B | 28.77B | 24.36B | 23.74B | 21.34B | 18.42B | 17.96B | 15.50B | 16.26B | 14.05B | 13.06B | 10.35B | 10.03B | 9.36B | 9.03B | 8.40B | 7.63B | 7.01B | 6.48B | 6.33B | 5.32B | 4.75B | 4.16B | 3.84B | 3.38B | 2.93B | 2.62B |
| Interest Income | 385.00M | 183.00M | 43.00M | 46.00M | 94.00M | 105.00M | 124.00M | 99.00M | 105.00M | 77.00M | 67.00M | 79.23M | 85.20M | 105.45M | 137.78M | 201.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 637.00M | 375.00M | 490.00M | 500.00M | 576.00M | 721.00M | 780.00M | 332.00M | 58.00M | 73.00M | 90.00M | 513.00M | 530.14M | 553.14M | 382.00M | 528.47M | 593.14M | 292.35M | 153.66M | 149.09M | 146.12M | 205.22M | 234.76B | 23.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.24B | 3.27B | 3.54B | 3.33B | 3.01B | 3.28B | 3.02B | 1.35B | 601.00M | 555.00M | 791.00M | 2.78B | 3.04B | 2.62B | 2.09B | 1.84B | 1.85B | 1.56B | 1.36B | 1.29B | 1.27B | 1.18B | 1.17B | 827.43M | 828.01M | 784.24M | 727.75M | 686.09M | 566.42M | 510.50M | 484.08M | 427.80M | 379.00M | 355.90M | 307.30M | 270.90M | 243.70M | 199.50M | 155.80M |
| EBITDA | 10.61B | 12.38B | 12.74B | 8.79B | 7.77B | 7.12B | 6.13B | 3.07B | 4.83B | 4.22B | 3.45B | 3.50B | 9.26B | 9.14B | 9.49B | 8.22B | 6.43B | 4.25B | 6.22B | 5.61B | 4.20B | 4.30B | 4.39B | 3.40B | 3.98B | 3.90B | 3.56B | 3.30B | 2.95B | 2.65B | 2.41B | 1.95B | 1.94B | 1.76B | 1.53B | 1.37B | 1.25B | 1.08B | 892.90M |
| EBITDA Ratio | 26.44% | 24.50% | 24.95% | 21.94% | 20.87% | 19.51% | 18.08% | 13.38% | 18.37% | 15.51% | 15.80% | 21.08% | 15.08% | 19.30% | 20.82% | 21.20% | 25.41% | 33.72% | 23.92% | 27.28% | 21.54% | 25.87% | 33.77% | 26.56% | 27.68% | 29.46% | 28.54% | 29.05% | 29.16% | 28.61% | 27.38% | 21.50% | 27.41% | 28.02% | 27.53% | 27.03% | 28.27% | 27.62% | 24.92% |
| Operating Income | 6.48B | 8.36B | 8.43B | 5.36B | 4.53B | 3.65B | 1.73B | 3.19B | 2.87B | 2.60B | 2.63B | 8.09B | 5.75B | 6.09B | 6.24B | 5.69B | 4.58B | 2.04B | 4.36B | 3.90B | 3.32B | 3.53B | 1.89B | 3.40B | 3.15B | 3.12B | 2.85B | 2.62B | 2.38B | 2.14B | 1.92B | 1.53B | 1.56B | 1.41B | 1.22B | 1.10B | 1.01B | 878.60M | 737.10M |
| Operating Income Ratio | 16.15% | 19.16% | 19.56% | 15.48% | 14.21% | 11.94% | 6.30% | 15.27% | 14.05% | 12.84% | 12.03% | 20.28% | 14.81% | 17.31% | 20.27% | 19.28% | 17.67% | 9.09% | 19.53% | 19.81% | 16.88% | 19.96% | 11.63% | 24.74% | 23.90% | 24.99% | 23.99% | 23.76% | 23.80% | 23.42% | 22.88% | 19.43% | 22.64% | 22.83% | 22.70% | 22.32% | 22.92% | 23.07% | 21.94% |
| Total Other Income/Expenses | 186.00M | -56.00M | -214.00M | -389.00M | -455.00M | -777.00M | 667.00M | -1.61B | 316.00M | -81.00M | -92.00M | -1.22B | -553.36M | -374.75M | 958.03M | 162.45M | -108.90M | 234.15M | 257.65M | 227.28M | 411.89M | 143.27M | -10.88M | 415.83M | 247.53M | 123.98M | 84.17M | 52.44M | 12.42M | 22.48M | 19.26M | 212.80M | -12.80M | -55.30M | -27.00M | -46.60M | -68.50M | -59.90M | -42.60M |
| Income Before Tax | 6.66B | 8.31B | 8.21B | 4.97B | 4.08B | 2.87B | 2.23B | 1.41B | 3.18B | 2.52B | 2.52B | 6.26B | 5.20B | 5.71B | 7.19B | 5.86B | 4.47B | 2.28B | 4.62B | 4.13B | 3.73B | 3.67B | 1.88B | 3.82B | 3.40B | 3.24B | 2.95B | 2.67B | 2.40B | 2.17B | 1.94B | 1.74B | 1.54B | 1.35B | 1.19B | 1.06B | 937.20M | 818.70M | 694.50M |
| Income Before Tax Ratio | 16.61% | 19.03% | 19.06% | 14.36% | 12.78% | 9.40% | 8.15% | 6.78% | 15.60% | 12.44% | 11.54% | 15.71% | 13.38% | 16.25% | 23.38% | 19.83% | 17.25% | 10.13% | 20.68% | 20.96% | 18.98% | 20.77% | 11.56% | 27.76% | 25.78% | 25.97% | 24.82% | 24.24% | 23.92% | 23.66% | 23.11% | 22.14% | 22.46% | 21.93% | 22.20% | 21.38% | 21.36% | 21.50% | 20.67% |
| Income Tax Expense | 941.00M | 1.37B | 1.14B | 497.00M | 390.00M | 539.00M | 1.88B | 350.00M | 577.00M | 797.00M | 138.00M | 300.00M | 470.00M | 1.09B | 1.45B | 1.12B | 863.33M | 559.62M | 1.25B | 949.76M | 981.18M | 879.71M | 332.76M | 1.03B | 951.13M | 907.37M | 855.48M | 787.52M | 706.62M | 650.01M | 544.10M | 499.70M | 455.50M | 385.00M | 334.40M | 303.40M | 304.60M | 278.20M | 229.20M |
| Net Income | 5.72B | 6.93B | 7.07B | 4.50B | 3.69B | 2.37B | 477.00M | 1.40B | 4.42B | 2.28B | 2.58B | 5.96B | 4.73B | 4.63B | 5.75B | 4.88B | 3.61B | 1.72B | 3.37B | 3.24B | 2.75B | 2.79B | 1.55B | 2.79B | 2.45B | 2.33B | 2.08B | 1.88B | 1.69B | 1.52B | 1.40B | 1.24B | 1.09B | 965.80M | 859.80M | 752.00M | 632.60M | 540.50M | 465.30M |
| Net Income Ratio | 14.27% | 15.88% | 16.42% | 12.99% | 11.56% | 7.74% | 1.74% | 6.71% | 21.68% | 11.28% | 11.79% | 14.95% | 12.17% | 13.15% | 18.68% | 16.53% | 13.92% | 7.64% | 15.10% | 16.44% | 13.99% | 15.80% | 9.52% | 20.27% | 18.56% | 18.71% | 17.50% | 17.09% | 16.87% | 16.56% | 16.64% | 15.78% | 15.83% | 15.68% | 15.98% | 15.23% | 14.42% | 14.20% | 13.85% |
| EPS | 3.30 | 3.94 | 3.97 | 2.52 | 2.07 | 1.35 | 0.27 | 0.95 | 3.00 | 1.51 | 1.66 | 3.78 | 3.01 | 2.99 | 3.72 | 3.16 | 2.34 | 1.12 | 2.17 | 2.07 | 1.76 | 1.79 | 1.00 | 1.80 | 1.59 | 1.52 | 1.35 | 1.21 | 1.06 | 0.93 | 0.84 | 0.74 | 0.64 | 0.56 | 0.49 | 0.42 | 0.35 | 0.29 | 0.25 |
| EPS Diluted | 3.27 | 3.91 | 3.94 | 2.50 | 2.06 | 1.34 | 0.27 | 0.94 | 2.94 | 1.50 | 1.64 | 3.75 | 3.01 | 2.97 | 3.70 | 3.13 | 2.31 | 1.12 | 2.16 | 2.06 | 1.75 | 1.78 | 0.99 | 1.78 | 1.57 | 1.49 | 1.33 | 1.19 | 1.06 | 0.93 | 0.84 | 0.74 | 0.64 | 0.56 | 0.49 | 0.42 | 0.35 | 0.29 | 0.25 |
| Weighted Avg Shares Out | 1.73B | 1.75B | 1.78B | 1.77B | 1.77B | 1.76B | 1.74B | 1.47B | 1.47B | 1.51B | 1.55B | 1.58B | 1.57B | 1.55B | 1.55B | 1.54B | 1.54B | 1.53B | 1.55B | 1.56B | 1.56B | 1.56B | 1.55B | 1.55B | 1.54B | 1.54B | 1.55B | 1.56B | 1.59B | 1.62B | 1.66B | 1.67B | 1.70B | 1.72B | 1.75B | 1.79B | 1.81B | 1.86B | 1.86B |
| Weighted Avg Shares Out (Dil) | 1.75B | 1.76B | 1.79B | 1.79B | 1.78B | 1.77B | 1.75B | 1.48B | 1.51B | 1.53B | 1.57B | 1.59B | 1.57B | 1.56B | 1.56B | 1.56B | 1.56B | 1.54B | 1.56B | 1.57B | 1.57B | 1.57B | 1.57B | 1.57B | 1.56B | 1.56B | 1.58B | 1.58B | 1.59B | 1.62B | 1.66B | 1.67B | 1.70B | 1.72B | 1.75B | 1.79B | 1.81B | 1.86B | 1.86B |
Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus
ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.
Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Abbott Laboratories will announce its Q3 results on the morning of 16th October, with earnings and topline growth largely expected to be in line with the Q2 trend. A year ago, all of Abbott's divisions had generated double-digit topline growth,...
Diabetes Products To Drive Abbott's Q3
Abbott (NYSE: ABT) will report its Q3 2024 results on Wednesday, Oct 16. We expect the company to post revenue of $10.6 billion and earnings of $1.20 on a per share and adjusted basis, aligning with the street expectations.
Abbott (ABT) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Evaluate the expected performance of Abbott (ABT) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping
Enrollment completed ahead of schedule in the global IDE for Abbott's Volt™ PFA System Global FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, receives U.S. Food and Drug...
Abbott (ABT) Earnings Expected to Grow: Should You Buy?
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
RBC Capital Raises Target Price for Abbott to $130
RBC Capital has recently adjusted its outlook on Abbott Laboratories (ABT, Financial), increasing its target price from $125 to $130. The firm continues to maintain an "Outperform" rating for the company, indicating a strong confidence in its potential for growth...
Why Abbott (ABT) Outpaced the Stock Market Today
Abbott (ABT) closed at $114.63 in the latest trading session, marking a +1.12% move from the prior day.
Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth
Abbott Laboratories's ABT MedTech portfolio is growing at a CAGR (compounded annual growing rate) of 11%-13%.
Source: https://incomestatements.info
Category: Stock Reports